Alliancebernstein L.P. purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,600 shares of the biotechnology company’s stock, valued at approximately $598,000. Alliancebernstein L.P. owned approximately 0.09% of CytomX Therapeutics at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Highbridge Capital Management LLC purchased a new position in CytomX Therapeutics during the fourth quarter valued at $158,000. Hillsdale Investment Management Inc. bought a new stake in shares of CytomX Therapeutics during the first quarter worth about $159,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of CytomX Therapeutics during the first quarter worth about $206,000. Strs Ohio bought a new stake in shares of CytomX Therapeutics during the first quarter worth about $207,000. Finally, American International Group Inc. boosted its stake in shares of CytomX Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,580 shares of the biotechnology company’s stock worth $217,000 after buying an additional 834 shares during the period. Hedge funds and other institutional investors own 52.75% of the company’s stock.
Shares of CytomX Therapeutics, Inc. (CTMX) opened at 13.53 on Friday. The stock has a 50 day moving average price of $14.54 and a 200-day moving average price of $14.59. CytomX Therapeutics, Inc. has a 12 month low of $9.85 and a 12 month high of $20.02. The company’s market capitalization is $498.81 million.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by $0.30. The firm had revenue of $8.75 million for the quarter, compared to analyst estimates of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. Analysts expect that CytomX Therapeutics, Inc. will post ($1.47) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Alliancebernstein L.P. Purchases New Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX)” was first posted by BNB Daily and is the property of of BNB Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/alliancebernstein-l-p-invests-598000-in-cytomx-therapeutics-inc-nasdaqctmx-updated.html.
Several analysts have weighed in on CTMX shares. Cowen and Company reaffirmed a “buy” rating on shares of CytomX Therapeutics in a report on Wednesday, June 28th. Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a research report on Wednesday, May 3rd. ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. HC Wainwright reiterated a “buy” rating on shares of CytomX Therapeutics in a research report on Monday, May 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $25.00 price objective on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. CytomX Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $25.60.
In related news, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total value of $37,500.00. Following the completion of the sale, the chief financial officer now directly owns 19,626 shares of the company’s stock, valued at $294,390. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Frederick W. Gluck sold 5,000 shares of the business’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $14.61, for a total transaction of $73,050.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,343 shares of company stock valued at $606,856. Insiders own 4.70% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.